Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report.
BACKGROUND
Plasma cell leukemia (PCL) is a rare lymphoproliferative disorder considered to be a variant of multiple myeloma. It is an aggressive disease with a poor clinical response to standard chemotherapeutic agents.


METHODS
A novel regimen consisting of bortezomib, doxorubicin, and dexamethasone is currently under active evaluation for the treatment of multiple myeloma. We employed this combination as front-line chemoinduction therapy for a case of primary PCL.


CONCLUSIONS
Complete remission was achieved with rapid normalization of hematologic parameters. The combination of bortezomib, doxorubicin and dexamethasone demonstrates promise in the treatment of PCL.
Chan
Steven M
SM
Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. brunom@stanford.edu.
George
Tracy
T
Cherry
Athena M
AM
Medeiros
Bruno C
BC